Google Übersetzer
Cytokinetics, Incorporated
About
76.94USD-1.12 -1.43%
Closed • Updated at 12:53 GMT+00:00Market Cap$9.57B
Volume1.11M
Beta0.57
RSI60.56
Gross Margin87.00%
Cytokinetics, Incorporated — investor relations, events, news, and company updates on 6ix.
Latest News
May 11 2026
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026
May 8 2026
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million
May 7 2026
Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock
May 5 2026
Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
May 5 2026
Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
Recent Videos
Cytokinetics Stock Surges as Heart Drug Breakthrough Stuns Investors
May 05, 2026
CYTK Financial Profile 2026: High Market Value Despite Negative Earnings
Apr 30, 2026
Cytokinetics Q4 2025 Earnings Call
Feb 26, 2026
Cytokinetics MYQORZO Approval: My Key Insight from the 8-K
Feb 19, 2026
Community Chat
Ask AI
Try asking